9MW2821 + Toripalimab vs 9MW2821 for 1st Line Locally Advanced or Metastatic Urothelial Carcinoma
A phase 2 trial of Toripalimab in bladder & urothelial cancer, run by Mabwell (Shanghai) Bioscience Co., Ltd., now recruiting.
Overview
9MW2821 + Toripalimab vs 9MW2821 for 1st Line Locally Advanced or Metastatic Urothelial Carcinoma is a phase 2 interventional study registered as NCT06823427 by Mabwell (Shanghai) Bioscience Co., Ltd., with 60 participants planned, started 2025-01-17 and due to reach its primary completion in 2026-06. Interventions recorded: 9MW2821 and Toripalimab (JS001 ).
Similar pages
not linked directly; found by shared links- Trial9MW2821 Combined With Toripalimab Injection in Subjects With Local Advanced or Metastatic Urothelial Cancer
Shares Toripalimab, Bladder & urothelial cancer and the tag pipeline.
- Trial9MW2821 Combined With Toripalimab in Perioperative Patients With Urothelial Cancer
Shares Toripalimab, Bladder & urothelial cancer and the tag pipeline.
- TrialPhase Ⅰ/Ⅱ Clinical Study to Evaluate ABO2011 in Advanced Solid Tumors
Shares Toripalimab and the tag pipeline.
- TrialA Study of WX390 Combined With Toripalimab in Patients With Advanced Solid Tumors
Shares Toripalimab and the tag pipeline.
- Trial9MW2821 in Combination With Toripalimab vs Standard Chemotherapy in Locally Advanced or Metastatic Urothelial Cancer
Shares Toripalimab, Bladder & urothelial cancer and the tag pipeline.
- TrialIntravesical Photodynamic Therapy ("PDT") in BCG-Unresponsive/Intolerant Non-Muscle Invasive Bladder Cancer ("NMIBC") Patients
Shares Bladder & urothelial cancer and the tag pipeline.
- TrialLEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve
Shares Bladder & urothelial cancer and the tag pipeline.
- TrialA Study of STM-416 Administered to Patients Undergoing TURBT for Recurrent Bladder Cancer
Shares Bladder & urothelial cancer and the tag pipeline.